4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis
Source Summary
LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis
Advertisement